Centivax

Accelerating the world's transition to a post-pathogen humanity.

San Francisco, United States · Founded 2019 · $92.0M raised

Employees
11–50
Founded
2019
Business Model
B2B
Total Funding
$92.0M
Last Round
$37.0M Series BMar 2026
Rounds
3

About

Centivax is a clinical-stage universal immunity company deploying a proprietary computational immune-engineering platform to develop broad-spectrum vaccines and therapeutic antibodies. Founded in 2019 by computational immunologist Jacob Glanville, the company's lead program is a universal influenza vaccine currently in Phase 1 clinical trials, which was awarded a Gates Foundation Grand Challenge. Centivax is also developing universal vaccines for other pathogens and antivenom therapies. The company is headquartered in South San Francisco, California and has raised over $55 million in funding.

Summary

Centivax is a Biotech company based in San Francisco, United States, founded in 2019. It has raised $92.0M in total across 3 rounds, most recently a $37.0M Series B round in Mar 2026. Investors include Structure Capital.

Tech & App Stack

1 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BMar 2026
$37.0M

Sign up to see all 3 rounds

Seed through Series B — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Centivax on Indexed.vc
<a href="https://indexed.vc/companies/centivax"><img src="https://indexed.vc/api/badge/company/centivax" alt="Centivax on Indexed.vc" width="260" height="76" /></a>